Scholar Rock (SRRK) Revenue & Revenue Breakdown
Scholar Rock Revenue Highlights
00
Scholar Rock Revenue by Period
Scholar Rock Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -100.00% |
2022-12-31 | $33.19M | 76.41% |
2021-12-31 | $18.82M | 22.16% |
2020-12-31 | $15.40M | -24.83% |
2019-12-31 | $20.49M | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | -100.00% |
2016-12-31 | $379.00K | - |
Scholar Rock Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $11.66M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | -100.00% |
2022-12-31 | $33.19M | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | -100.00% |
2022-03-31 | $33.19M | 719.78% |
2021-12-31 | $4.05M | -25.90% |
2021-09-30 | $5.46M | 18.91% |
2021-06-30 | $4.59M | -2.40% |
2021-03-31 | $4.71M | 37.02% |
2020-12-31 | $3.44M | 13.14% |
2020-09-30 | $3.04M | -22.13% |
2020-06-30 | $3.90M | -22.47% |
2020-03-31 | $5.03M | -33.58% |
2019-12-31 | $7.57M | 58.63% |
2019-09-30 | $4.77M | -5.26% |
2019-06-30 | $5.04M | 62.23% |
2019-03-31 | $3.11M | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | - |
Scholar Rock Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ARVN | Arvinas | $78.50M | $102.40M |
RLAY | Relay Therapeutics | $25.55M | - |
IDYA | IDEAYA Biosciences | $23.39M | - |
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
ANAB | AnaptysBio | $17.16M | $30.02M |
MGTX | MeiraGTx | $14.02M | $10.91M |
RVMD | Revolution Medicines | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
IGMS | IGM Biosciences | $2.13M | $516.00K |
PLRX | Pliant Therapeutics | $1.58M | - |
KROS | Keros Therapeutics | $151.00K | $37.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
PASG | Passage Bio | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
SRRK | Scholar Rock | - | - |